Microbiome-Targeted Interventions for Pediatric Asthma and Allergic Diseases: Current and Emerging Approaches.

Allergic diseases are among the most common chronic diseases of childhood and remain a major public health challenge. Increasing evidence indicates that the early-life gut microbiome plays a central role in immune maturation, making it an attractive target for allergy prevention. During the first 1000 days of life, interactions between the developing microbiome and the immune system help establish immune tolerance, while disruptions to this process increase the risk of asthma and allergic diseases. Current microbiome-targeted strategies largely focus on optimizing early-life microbial exposures through interventions such as mode of delivery, antibiotic stewardship, breastfeeding, and exposure to diverse environmental microorganisms. These approaches are already incorporated into public health recommendations and promote healthy microbiome development without directly manipulating microbial communities. Newer approaches seek to intervene more precisely through microbial transfer therapies, live biotherapeutic products, prebiotics, postbiotics, and microbial metabolite-based therapies. Although several have shown encouraging preclinical and early clinical results, evidence supporting routine clinical use remains limited. The next generation of microbiome therapeutics is likely to be defined less by changing which microbes are present than by restoring the microbial functions that establish immune tolerance. This conceptual advance is driving the development of increasingly targeted microbiome-based interventions and provides a framework for the next generation of allergy prevention strategies. Translating these mechanistic insights into safe, effective therapies that complement established public health measures represents the next major challenge in preventing asthma and allergic diseases.